In its new study, Persistence Market Research offers insights about key factors driving demand for phenylketonuria treatment. The study points toward the adoption of PKU formula and PKU treatment based on protein ingredients and finished PKU products. Nutraceutical companies hold close to one-third of the market share, globally. The report also tracks global sales of PKU ingredients in the form of finished products in over 20 high-growth markets, along with analysis of the impact of COVID-19 on the life science industry in general, and phenylketonuria treatment in particular.

1. Digitized Specificity to Drive the
Phenylketonuria Treatment Market
The Phenylketonuria Treatment Market is expected to grow step-wise in the next 10 years.
Video-calling has penetrated the healthcare vertical, resulting in effective long-distance
monitoring. Virtual doctor visits are followed by superlative telemedicine, which results in
cost-effectiveness as well as various options to choose from (regarding medical
practitioners). This would be how the healthcare vertical go in the upcoming period.
Phenylketonuria (PKU) is an inherited disorder caused by excess of phenylalanine in the
blood, which can lead to severe intellectual disabilities. There is no cure for phenylketonuria
as yet, and dietary management is the only option to maintain the phenylalanine level in the
body. Untreated infants with PKU tend to have unusually light eye, skin, and hair colour due
to excess of phenylalanine levels interfering with melanin. Neurological symptoms such as
seizures, abnormal muscle movement, tremors, or involuntary movement are some of the
symptoms mainly observed in such patients.
Get Sample Copy of this
Report@ https://www.persistencemarketresearch.com/samples/14410
Rising prevalence of phenylketonuria among newborns and surging demand for novel
formulations to treat the disease have led to increased opportunities for market players.
Stakeholders are investing more in research & development for novel treatment solutions
within the nutraceutical industry.
According to the latest report published by Persistence Market Research, the
global phenylketonuria treatment market for protein ingredients was valued at US$ 325.9
Mn in 2019, and is predicted to witness an impressive CAGR of over 6% during the forecast
period (2020–2030). Similarly, the market for finished products was valued at US$ 565.8
Mn in 2019, and is predicted to witness an impressive CAGR of around 7% through 2030.
Company Profiles:
 Arla Foods Ingredients Group P/S
 Archer Daniels Midland Company
 BASF SE
 Chr. Hansen
 Cargill, Incorporated
 Seidler Chemical Co, Inc.
 Nestlé S.A. (Vitaflo International)
 Reckitt Benckiser Group plc. (Mead Johnson & Company, LLC.)
 Abbott Laboratories
 APR Applied Pharma Research S. A.
 Ajinomoto Co., Inc.
 VitafriendsPKU
 Pristine Organics Pvt. Ltd

2. Request for
Methodology@ https://www.persistencemarketresearch.com/methodology/14410
Key Takeaways from Phenylketonuria Treatment Market Study
For Protein Ingredients
 Essential and non-essential amino acid ingredients are expected to contribute more than
1/3 of the revenue share in the market.
 Powder blend form is expected to gain traction in phenylketonuria treatment, accounting
for more than 90% share throughout the forecast years.
 By targeted customer, consumer healthcare companies hold the highest share of more than
80% in this space.
 By sales channel, industry sales of protein ingredients are dominating the market.
 North America holds the highest share in the global phenylketonuria treatment market,
owing to the presence of big market players and growing research & development efforts in
the region.
 Key players are focused on expanding their product portfolios and expansion at regional
levels through collaborations and acquisitions.
 The market in the U.S. is projected to be the fastest-growing at a CAGR above 6.5% through
2030. The U.S. holds a big portion of the market revenue and accounts for more than 90% in
North America.
For Finish Products
 Essential and non-essential amino acids are expected to contribute more than 1/3 of the
revenue share in the market.
 The powder & granules form is expected to dominate phenylketonuria treatment,
accounting for a share of more than 50% through 2030.
 By targeted customer, adults account for the highest market share of more than 50%.
 By sales channel, hypermarkets and supermarkets will hold the highest share throughout
the forecast period.
 North America holds more than 40% of the global phenylketonuria treatment market share.
 Key market players are focusing on expansion of their product portfolios by highly investing
in the research & development sector, and are generating high revenue through
collaborations and acquisitions.
 The market in the U.S. is projected to be the fastest-growing, and will expand at a CAGR
close to 6% through 2030. The U.S. holds a big portion of the market revenue, and accounts
for more than 90% share in North America.
“Increasing prevalence of PKU and rising adoption of PKU diets will upswing the global
phenylketonuria treatment market over the coming years,” says an analyst of Persistence
Market Research.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/14410
Collaborations & Acquisitions Key Strategies amongst Market Players
Prominent players in the phenylketonuria treatment market are firming their product
ranges through acquisitions and reaching out to emerging markets. Increasing investments

3. and manufacturing capacity expansion are expected to favour growth of the global market
over the forecast period.
 For instance, Mead Johnson Nutrition Company was acquired by the Reckitt Benckiser
Group plc (RB). Mead Johnson is now a division of RB, adding its globally-recognized brands,
including Phenyl-Free® 1, an iron-fortified PKU infant formula and medical food powder for
infants and young children with documented phenylketonuria.
 Additionally, Abbott Laboratories collaborated with Syngene to inaugurate its first nutrition
research & development centre in India.
Various players in the phenylketonuria treatment market are focusing on research &
development, product launches, and advanced solutions to strengthen and expand their
product portfolios.
 For instance, Vitaflo USA introduced PKU Sphere™, a powdered, low phenylalanine medical
food used in the dietary management of phenylketonuria. The medical food formula is a
Glycomacropeptide (GMP)-based medical food containing a balanced mix of GMP and
amino acids.
 Ajinomoto Co., Inc. introduced a new product line, Glytactin BUILD 20/20™ and Glytactin
RTD Lite, new PKU formulas featuring the next generation of Glytactin with 40% less Phe
per gram of PE than all other GMP-based PKU medical foods.
What Does the Report Cover?
Persistence Market Research offers a unique perspective and actionable insights on the
phenylketonuria treatment market in its latest study, presenting historical demand
assessment of 2015 – 2019 and projections for 2020 – 2030. The research study is based on
PKU ingredients (protein ingredient [Glycomacropeptide (GMP) and essential and non-
essential amino acids] and finish products [Glycomacropeptide (GMP) and essential and
non-essential amino acids]), targeted customer (protein ingredients [consumer healthcare
companies, pharmaceutical companies, and contract manufacturing companies (CMOs)] and
finish products [adults, paediatrics, and pregnant women]), form (protein ingredients
[powder blend and granules], finish products [powder & granules, tablets, capsules, powder
sachets, ready-to-drink, shakes, and other]), and sales channel (protein ingredients [industry
sales], finish products [hospital pharmacies, retail pharmacies, online pharmacies, and
hypermarkets & supermarkets]), across seven key regions of the world.
About us: Persistence Market Research
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com